“Durable maintenance of EASI-90 with amlitelimab in adults with moderate-to-severe atopic dermatitis: 52-week results from the STREAM-AD phase 2b trial” (2025) SKIN The Journal of Cutaneous Medicine, 9(6), p. s606. doi:10.25251/yhn4cs07.